Nilotinib reduces DDR-1 expression [6] and reduces its phosphorylation (activation) in the CSF of AD patients [6], while the activation of DDR1 increases microglial activity and MMPs [33,34]. This evidence concerns the gene DDR1 and Alzheimer disease.